| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 18.05.
| Exelixis' Management Presents at Bank of America Merrill Lynch 2012 Health Care Conference (Transcript) | | 3 | Seeking Alpha |
| 17.05.
| Ariad Pharmaceuticals, ArQule, Exelixis, Aveo, Other Cancer Drug Stocks Fall | | 11 | Minyanville |
| 16.05.
| Reminder: Exelixis Announces Data Presentations, Webcast of Investor Briefing in Conjunction With 2012 ASCO Annual Meeting | | 36 | Business Wire |
| -- Oral Presentations for Medullary Thyroid Cancer,
Castration-Resistant Prostate Cancer, Renal Cell Carcinoma and
Hepatocellular Carcinoma
-- Investor...
Mehr lesen zu:
Reminder: Exelixis Announces Data Presentations, Webcast of Investor Briefing in Conjunction With 2012 ASCO Annual Meeting | |
| 10.05.
| Exelixis Announces May 17th Webcast of Presentation at the Bank of America Merrill Lynch 2012 Health Care Conference | | 32 | Business Wire |
| Exelixis, Inc. (NASDAQ:EXEL) announced today that Michael M. Morrissey,
Ph.D., the company's president and chief executive officer, will present
at the Bank of America...
Mehr lesen zu:
Exelixis Announces May 17th Webcast of Presentation at the Bank of America Merrill Lynch 2012 Health Care Conference | |
| 10.05.
| Exelixis' Management Presents at Deutsche Bank Securities Annual Health Care Conference (Transcript) | | 5 | Seeking Alpha |
| 04.05.
| Biotech Stock Mailbag: Exelixis, Protalix, Arena | | 10 | The Street |
| 04.05.
| Exelixis's CEO Discusses Q1 2012 Results - Earnings Call Transcript | | 4 | Seeking Alpha |
| 03.05.
| Exelixis Announces First Quarter 2012 Financial Results | | 24 | Business Wire |
| Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the
quarter ended March 31, 2012.
The financial results for the quarter reflect Exelixis'...
Mehr lesen zu:
Exelixis Announces First Quarter 2012 Financial Results | |
| 03.05.
| Exelixis Expands the Cabozantinib Development Program Through NCI-CTEP Collaboration | | 28 | Business Wire |
| -- Initial Program of 12 Additional Trials, Including Four Randomized
Phase 2 Trials, Approved under NCI-CTEP Collaboration --
Exelixis...
Mehr lesen zu:
Exelixis Expands the Cabozantinib Development Program Through NCI-CTEP Collaboration | |
| 02.05.
| Exelixis Announces May 8th Webcast of Presentation at the Deutsche Bank Securities 37th Annual Health Care Conference | | 41 | Business Wire |
| Exelixis, Inc. (NASDAQ: EXEL) announced today that Frank Karbe, the
company's executive vice president and chief financial officer, will
present at the upcoming Deutsche...
Mehr lesen zu:
Exelixis Announces May 8th Webcast of Presentation at the Deutsche Bank Securities 37th Annual Health Care Conference | |
| 30.04.
| Exelixis: Uncovering Value | | 8 | Seeking Alpha |
| 23.04.
| Pharmaceutical Companies Look to Biotech Industry to Combat Losses From Expiring Patents / The Paragon Report Provides Stock Research on Biosante Pharmaceuticals Inc. and Exelixis, Inc. | | 72 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 04/23/12 -- Mergers and Acquisitions have been a hot topic in in the Biotechnology Industry recently. Pharmaceutical giants face an unprecedented number of patent expirations...
Mehr lesen zu:
Pharmaceutical Companies Look to Biotech Industry to Combat Losses From Expiring Patents / The Paragon Report Provides Stock Research on Biosante Pharmaceuticals Inc. and Exelixis, Inc. | |
| 19.04.
| Exelixis Announces May 3rd Webcast of First Quarter 2012 Financial Results Conference Call | | 37 | Business Wire |
| Exelixis, Inc. (NASDAQ:EXEL) will release its first quarter 2012
financial results on Thursday, May 3, 2012, after the markets close. The
announcement will be followed...
Mehr lesen zu:
Exelixis Announces May 3rd Webcast of First Quarter 2012 Financial Results Conference Call | |
| 12.04.
| Exelixis Trading Higher Today on Above-Average Volume, Consistent With Trend | | 6 | SmarTrend |
| 05.03.
| Exelixis Announces Initiation of Investigator-Sponsored Clinical Trial Combining Cabozantinib and Abiraterone in Men With Castration-Resistant Prostate Cancer | | 50 | Business Wire |
| Exelixis Inc. (NASDAQ:EXEL) today announced the initiation of a phase 1
dose-finding trial of cabozantinib in combination with abiraterone in
men with metastatic castration-resistant...
Mehr lesen zu:
Exelixis Announces Initiation of Investigator-Sponsored Clinical Trial Combining Cabozantinib and Abiraterone in Men With Castration-Resistant Prostate Cancer | |
| 01.03.
| Exelixis Announces March 6 Webcast of Presentation at the Cowen Health Care Conference | | 31 | Business Wire |
| Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey,
Ph.D., the company's president and chief executive officer, will present
at the 2012 Cowen Health...
Mehr lesen zu:
Exelixis Announces March 6 Webcast of Presentation at the Cowen Health Care Conference | |
| 27.02.
| Cancer Treatments Evolve - Exelixis and Seattle Genetics Look to Lead / Five Star Equities Provides Stock Research on Exelixis & Seattle Genetics | | 49 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 02/27/12 -- Advances in cancer screening and treatment has caused the death rate from cancer to drop dramatically in recent years. Cancer death rates dropped by 1.8...
Mehr lesen zu:
Cancer Treatments Evolve - Exelixis and Seattle Genetics Look to Lead / Five Star Equities Provides Stock Research on Exelixis & Seattle Genetics | |
| 21.02.
| Exelixis Announces February 28 Webcast of Presentation at the Citi Global Health Care Conference | | 30 | Business Wire |
| Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey,
Ph.D., the company's president and chief executive officer, will present
at the 2012 Citi Global...
Mehr lesen zu:
Exelixis Announces February 28 Webcast of Presentation at the Citi Global Health Care Conference | |
| 15.02.
| Exelixis Announces Closing of Public Offering of Common Stock and Exercise in Full of Option to Purchase Additional Shares | | 32 | Business Wire |
| – Raises $65.0 Million in Net Proceeds –
Exelixis, Inc. (Nasdaq: EXEL) today announced the completion of its
underwritten public offering of 12,650...
Mehr lesen zu:
Exelixis Announces Closing of Public Offering of Common Stock and Exercise in Full of Option to Purchase Additional Shares | |
| 10.02.
| Exelixis Announces February 14 Webcast of Presentation at 14th Annual BIO CEO & Investor Conference | | 54 | Business Wire |
| Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey,
Ph.D., the company's president and chief executive officer, will present
at the 14th annual BIO...
Mehr lesen zu:
Exelixis Announces February 14 Webcast of Presentation at 14th Annual BIO CEO & Investor Conference | |
